Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1538-1542 , December 2009

Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation

  • Trudy N. Small

      Affiliations

    • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
    • Corresponding Author InformationCorrespondence and reprint requests: Trudy N. Small, MD, Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
    • ,
  • Andrew D. Zelenetz

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Ariela Noy

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • R. David Rice

      Affiliations

    • Department of Nursing, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Tanya M. Trippett

      Affiliations

    • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Lauren Abrey

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Carol S. Portlock

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Emily J. McCullagh

      Affiliations

    • Department of Nursing, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Jill M. Vanak

      Affiliations

    • Department of Nursing, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Ann Marie Mulligan

      Affiliations

    • Department of Nursing, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Craig H. Moskowitz

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Received 18 June 2009 ,Accepted 20 July 2009.

References 

  1. Cherry JD. Epidemiology of pertussis. Pediatr Infect Dis J. 2006;25:361–362
  2. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;15(RR-17):1–37
  3. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1–34
  4. Rothstein E, Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J. 2005;24:S44–S47
  5. Centers for Disease Control and Prevention . National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System, 1996-2004. Atlanta, GA: Centers for Disease Control and Prevention; 2005;
  6. Food and Drug Administration. Product approval information–licensing action, package insert. Adacel™ (sanofi Pasteur) tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed. Available from: http://www.fda.gov/cber/lable/tdaave012306LB.pdf. Accessed June 1, 2009.
  7. Food and Drug Administration. Product approval information–licensing action, package insert. BOOSTRIX® (GlaxoSmithKline Biologicals) tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed. Available from: http://www.fda.gov/cber/label/tdapgla122905LB.pdf. Accessed June 1, 2009.
  8. Centers for Disease Control and Prevention . FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:374–375
  9. Small TN, Rice RD, McCullagh E, et al. Vaccine efficacy following autologous peripheral blood stem cell transplant for lymphoma. Blood. 2007;110:603
  10. McIntyre PB, Burgess MA, Eagan A, et al. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years postvaccination. Vaccine. 2009;27:1062–1066
  11. Launay O, Toneatti C, Bernede C, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccines. 2009;5:1–6
  12. Edelman K, He Q, Makinen J, et al. Immunity to pertussis five years after booster immunization in adolescence. Clin Infect Dis. 2007;44:1271–1277
  13. Hoppe BS, Moskowitz CH, Filippa DA, et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol. 2008;26:1858–1864
  14. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688
  15. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616–623
  16. Center for International Blood and Marrow Transplant Research database. Accessed June 1, 2009.
  17. Hammarstrom V, Pauksen K, Bjorkstrand B, et al. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant. 1998;22:67–81
  18. Nordøy T, Husebekk A, Aaberge IS. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT: serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant. 2001;28:681–687
  19. Gandhi MK, Egner W, Sizer L, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 2001;28:775–781
  20. Centers for Disease Control and Prevention . Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep. 2000;49:1–128
  21. Ljungman P, Engelhard D, de la Cámara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005;35:737–746

 Financial disclosure: See Acknowledgments on page 1541.

PII: S1083-8791(09)00348-6

doi: 10.1016/j.bbmt.2009.07.018

Biology of Blood and Marrow Transplantation
Volume 15, Issue 12 , Pages 1538-1542 , December 2009

Article Tools

* Image Usage & Resolution